摘要 |
The invention provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester or salt or solvate of such ester, of a compound of formula (I) in which: R<SUP>0 </SUP>is halogen, C<SUB>1-6</SUB>alkyl, C<SUB>1-6</SUB>alkoxy, C<SUB>1-6</SUB>alkoxy substituted by one or more fluorine atoms, or O(CH<SUB>2</SUB>)<SUB>n</SUB>NR<SUP>4</SUP>R<SUP>5</SUP>; R<SUP>1 </SUP>and R<SUP>2 </SUP>are independently selected from H, C<SUB>1-6</SUB>alkyl, C<SUB>1-6</SUB>alkyl substituted by one or more fluorine atoms, C<SUB>1-6</SUB>alkoxy, C<SUB>1-6</SUB>hydroxyalkyl, SC<SUB>1-6</SUB>alkyl, C(O)H, C(O)C<SUB>1-6</SUB>alkyl, C<SUB>1-6</SUB>alkylsulphonyl, C<SUB>1-6</SUB>alkoxy substituted by one or more fluorine atoms, O(CH<SUB>2</SUB>)<SUB>n</SUB>CO<SUB>2</SUB>C<SUB>1-6</SUB>alkyl, O(CH<SUB>2</SUB>)<SUB>n</SUB>SC<SUB>1-6</SUB>alkyl, (CH<SUB>2</SUB>)<SUB>n</SUB>NR<SUP>4</SUP>R<SUP>5</SUP>, (CH<SUB>2</SUB>)<SUB>n</SUB>SC<SUB>1-6</SUB>alkyl or C(O)NR<SUP>4</SUP>R<SUP>5</SUP>; with the proviso that when R<SUP>0 </SUP>is at the 4-position and is halogen, at least one of R<SUP>1 </SUP>and R<SUP>2 </SUP>is C<SUB>1-6</SUB>alkylsulphonyl, C<SUB>1-6</SUB>alkoxy substituted by one or more fluorine atoms, O(CH<SUB>2</SUB>)<SUB>n</SUB>CO<SUB>2</SUB>C<SUB>1-6</SUB>alkyl, O(CH<SUB>2</SUB>)<SUB>n</SUB>SC<SUB>1-6</SUB>alkyl, (CH<SUB>2</SUB>)<SUB>n</SUB>NR<SUP>4</SUP>R<SUP>5 </SUP>or (CH<SUB>2</SUB>)<SUB>n</SUB>SC<SUB>1-6</SUB>alkyl, C(O)NR<SUP>4</SUP>R<SUP>5</SUP>; R<SUP>3 </SUP>is C<SUB>1-6</SUB>alkyl or NH<SUB>2</SUB>; R<SUP>4 </SUP>and R<SUP>5 </SUP>are independently selected from H and C<SUB>1-6</SUB>alkyl or, together with the nitrogen atom to which they are attached, form a 4-8 membered saturated ring; and n is 1-4; and an inhibitor of the release, or action, of tumour necrosis factor alpha.
|